Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 29 ... statins, and that there was a tendency toward a lower risk of gallstone disease for high-dose statin use compared with low-dose exposure. A substantially increased gallstone risk ... the results," the researchers write.The authors add that the observed risk reduction suggests a class effect for all statins, and that there was a tendency toward a lower ...
2009 NOV 23 ... to onset of relief was significantly shorter with Cl esterase inhibitor concentrate at a dose of 20 U/kg than with placebo (0.5 vs 1.5 hours; P = .0025), whereas with 10 U/kg, the ... shorter than with placebo (1.2 vs 1.5 hours; P = .2731). Compared with placebo, the reduction in time to onset of relief was greatest for severe attacks (0.5 vs 13.5 hours). The ...
2009 NOV 27 ... uptake in the brain was fast and sufficient, with values of similar to 4% injected dose per gram," wrote E.G. Maestrup and colleagues, University of Munster.The ... was validated in blocking studies by preapplication of haloperidol, and significant reduction in the uptake of radioactivity was observed in the brain and peripheral organs ...
2009 NOV 23 ... assigned to receive intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins) or standard statin therapy (atorvastatin, 10 mg/d, or equivalent dose ... to evaluate whether intensive treatment with statins for 2 to 5 years results in more reduction of cardiovascular events in patients with ACS compared to the standard statin therapy. A ...
2009 NOV 23 ... wrote M.S. Ghaffari and colleagues.The researchers concluded: "Single dose of topical 1% tropicamide resulted in statistically significant reduction in Schirmer ...
2009 NOV 23 ... galectin-9 suppressed the proliferation of lymphocytes mixed lymphocyte reactions in a dose- and beta-galactoside-dependent manner. In vivo, galectin-9 treatment from day 1 to day ... Furthermore, the intragraft transcriptional profiling in galectin-9-treated group showed reduction of IFN-gamma and IL-17 mRNA but elevation of Ebi-3 and galectin-9 mRNA. Flow cytometry ...
2009 NOV 23 ... concentrations. Furthermore, invasion and motility of 5-8F cells are decreased in a dose-and time-dependent manner, resulting in 73.0% invasion and 67.0% motility inhibition at ... of berberine on phospho-Ezrin were dependent on the suppression of Rho kinase activity. Reduction of Ezrin phosphorylation at Thr(567) by berberine was associated with its inhibitory ...
2009 NOV 23 ... whether predetermined contact frequency with the study teamand endpoint insulin dose are associated with study outcomes in basal insulin initiation trials in type 2 ... "Using data from the selected studies, contact frequency was plotted against HbA(1c) reduction and endpoint insulin dose. The importance of face-to-face vs telephone contact was also ...
2009 NOV 23 ... inhibited VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner in vitro. Cell proliferation was inhibited by 42 and 64% in HUVECs and ... of 10 and 30 mc M carebastine, respectively. Carebastine (20 mc M) caused a significant reduction (70-86%; p< 0.01) in topological parameters of the capillary network produced in ...
2009 NOV 23 ... model. CHM-1 induced CT-26 cell viability inhibition and morphologic changes in a dose-dependent and time-dependent manner and the approximate IC50 was 742.36 nM. CHM-1 ... cytochrome c, AIF, Bax, BAD, cleavage of pro-caspase-9, and -3. The significant reduction of caspase-9 and -3 activity and increasing the viable CT-26 cells after pretreated with ...
2009 NOV 23 ... of DHEA to estradiol. Our results show that DHEA inhibited cell proliferation in a dose-dependent manner in the three cell lines; the DHEA IC50 doses were 50, 60 and 70 mc M ... crystal staining and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reduction. Flow cytometry was used to evaluate the phases of the cell cycle, and cell death was ...
2009 NOV 23 ... albeit at higher concentrations, which is a major cause of their toxicity and may be a dose-limiting factor in oxime therapy." "To assess the efficacy of the ... which was significantly (p <or=0.05) better than all other tested oximes. Marked reduction in mortality was also achieved by K-48 and the three new bispyridinium oximes containing ...
2009 NOV 23 ... the placebo group died (sudden cardiac death), and five patients in the three darusentan dose groups combined had cardiac-related serious adverse events. Darusentan provides ... combined had cardiac-related serious adverse events. Darusentan provides additional reduction in blood pressure in patients who have not attained their treatment goals with three or ...
2009 NOV 23 ... for patient and organ motion during the treatment session, which can allow more accurate dose targeting." In addition to being faster and requiring fewer monitor units, ... of the American Society for Radiation Oncology (ASTRO) in Chicago.(1) "The reduction in monitor units is important because it limits the degree to which patients are exposed ...
2009 NOV 26 ... efficacy are lacking. This study from four Australian centers examined whether low-dose, continuous oral antibiotic therapy prevents urinary tract infection in predisposed ... interval, 0.40 to 0.93; P = 0.02 by the log-rank test). In the antibiotic group, the reduction in the absolute risk of urinary tract infection (6 percentage points) appeared to be ...
2009 NOV 25 ... IEEE Transactions on Nuclear Science report."In some CWO samples, the dose of 10(3) Gy caused destruction of defects responsible for induced absorption. Doping by ... caused destruction of defects responsible for induced absorption. Doping by Li leads to reduction of defects responsible for color and trapping centers in CWO crystals," wrote I.A. ...
2009 NOV 23 ... studies are difficult to compare because of differences in study design, probiotic dose, strain, and duration of therapy, some studies show symptom improvement. Lactobacilli ... has abnormal small-intestine bacterial overgrowth (SIBO), or in particular a significant reduction in the amount of intraluminal Bifidobacteria or Lactobacilli, with consequences like the ...
2009 NOV 28 -- According to a study from Rome, Italy, "Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants. We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants......
2009 NOV 23 ... treatment with TOK-001 in patients with CRPC. The Phase 1 component of the trial is a dose-finding study to evaluate escalating dose levels of TOK-001 and is expected to enroll ... lyase inhibitor currently in Phase 3 clinical trials and the compound has demonstrated reduction in prostate-specific antigen (PSA) levels. Notably, TOK-001 is the first investigational ...
2009 NOV 23 ... Allowance for one of our patent applications with claims that cover the use of our low-dose sublingual Intermezzo=AE formulation. Transcept is actively pursuing additional patents ... The decrease was partially offset by severance expense incurred in connection with the reduction in force announced in August 2009. Research and development expense included non-cash ...
